

# YUHAN CORPORATION

## Company Introduction

December 2023



# YUHAN CORPORATION

## Founder of Yuhan, Dr. Ilhan New


Korean activist & entrepreneur  
Donated all his wealth to a public education foundation



- Pharmaceutical Business
- Overseas Business (CDMO service for small molecules)
- Household & Healthcare Business
- Animal Healthcare & Dental Business
- Research & Development
- cGMP plants

Core Business Areas

# YUHAN's Worldwide Locations



**3** on-site R&BD open innovation offices

# R&D Strength

- Fully integrated R&D teams covering from discoveries to clinical developments, with a strong point in translational research
- Translational research strength includes swift development capability from early to clinical stage
- Engaging various collaboration models to maximize the value of assets (licensing, R&D-based JV, early research collaborations)



- Early stage Program
- Basic Science
- Platform Technology

## Right target

- ✓ Strong link between target and disease
- ✓ Differentiated efficacy
- ✓ Available and predictive biomarkers

## Right tissue

- ✓ Adequate bioavailability and tissue exposure
- ✓ Definition of PD biomarkers
- ✓ Clear understanding of preclinical and clinical PK/PD

- Global Clinical Trial
- Approval/Marketing

# Open Innovation: Values we seek

## Oncology



- Targeted anticancer agents: Assets enabling biomarker-driven patient selection with feasible PD markers
- Immuno-oncology: Mechanisms involved in innate or adaptive immune response

## Metabolism/Fibrosis



- Novel mechanisms of action targeting metabolic disease or tissue fibrosis (pulmonary, hepatic, renal fibrosis) with a strong disease link

## Allergy/Inflammation



- Directly treating the disease cause, rather than just managing symptoms
- Novel targets with strong scientific evidences

## Emerging technology



- Targeted protein degradation: Harnessing new E3 ligases, novel E3 ligase binders, novel target proteins of interest (POI), alternative TPD modalities (LYTAC, AUTAC, etc..)
- Drug RNA delivery technology: Novel lipid nanoparticles or polymer nanoparticles, Tissue targeting to the CNS (including BBB shuttle for biologics), immune system, or tumors
- Therapeutic mRNA platform with improved mRNA stability and/or translational efficacy (e.g. circular RNA)



Thank you